Resolution of Eosinophilia after Treatment of Cutaneous Gnathostomiasis

Kanyarat Kraivichian MD*, Surang Nuchprayoon MD, PhD*, Padet Siriyasatien MD, PhD*, Wilai Saksirisamphan MSc*, Issarang Nuchprayoon MD, PhD**

* Department of Parasitology, Faculty of Medicine, Chulalongkorn University
** Department of Pediatrics, Faculty of Medicine, Chulalongkorn University

The present study was to investigate the dynamics of eosinophil in peripheral blood of patients with cutaneous gnathostomiasis before and after worm removal. The total of 28 proven cases of cutaneous gnathostomiasis treated by albendazole were included in the present study. The absolute eosinophil count (AEC) was higher than 500/μl during infestation in almost all the patients, the positive rate was 89%, and significantly decreased to normal level after receiving albendazole and worm removal within 3 months in 96%. In conclusion, an increase of AEC is another important hallmark of cutaneous gnathostomiasis and this parameter could be the earlier indicator for responsiveness to treatment.

Keywords: Gnathostomiasis, Eosinophilia, Albendazole

In addition to the increase in the number of circulating eosinophils in the patient with suspected and proven cases of cutaneous gnathostomiasis, a massive eosinophil infiltration can be noted either at the time of the parasite invasion or migration, suggesting that eosinophil may play a pivotal role in the host defense during current infection with this parasite (9). Unfortunately, the correlation between clinical features of the disease and eosinophilia has not yet been studied. Absolute eosinophil count in the peripheral blood might be used as the indicator that relates to screening, effect of treatment and follow-up in cutaneous gnathostomiasis. The aim of the study was to investigate the dynamics of eosinophil before and after treatment with albendazole and worm removal.

Material and Method

The study populations were recruited from the previous studies (10,11). All of the selected 28 patients were diagnosed with cutaneous gnathostomiasis based on 1) clinical manifestation, that is, a history of subcutaneous migratory swelling; 2) stool examination results negative for other parasites; 3) a history of eating raw freshwater fish, crab, snake, bird or chicken and 4) worm discovery during the follow up period. The following
information was extracted from each medical record: demographic information including gender and age, domicile and previous medical treatment. Clinical assessment and blood examination for absolute eosinophil count were evaluated before and after treatment and following treatment once a month for 12 months or until AEC<500/ul. Eosinophilia (AEC>500/ul) was classified as mild eosinophilia (AEC between 500 and 1500/ul), moderate (AEC between 1500 and 5000/ul), or severe (AEC>5000/ul). The date of worm discovery was also recorded. All patients were treated with 400-800 mg. of albendazole per day for 21 days. Patients who had a history of allergic conditions were excluded from the present study.

Statistical analysis

The data were recorded and analyzed by using SPSS 10.0. Numerical data were summarized using descriptive statistics. Time to resolution of eosinophilia was analysed by Kaplan-Meier analysis.

Results

There were 28 patients included in the present study; 7 males and 21 females, with a mean age of 30.1 ±9.8 years (range 15-57 years). The skin involvement site and the severity of eosinophilia at the time of diagnosis are shown in Table 1. Among all the 28 patients with gnathostomiasis, the AEC ranged from 255 to 12,800/ul, with a geometric mean of 989/ul. Eosinophilia (AEC>500/ul) was present in 25 of 28 patients thus the positive rate of eosinophilia in cutaneous gnathostomiasis was 89%. 21 of the 28 patients (75%) had mild eosinophilia and only one patient had severe eosinophilia. After treatment with albendazole, the worm migrated superficially toward the epidermis and could be manually or surgically extracted and removed from all the patients. The parasitic worms were removed between 4 and 45 days (average 14.0±9.9 days, median 10.5 days) after treatment. Around 2 weeks after parasite removal, 3 of 25 patients had a transient rise in eosinophil count, from 525-1910/ul to 634-2050/ul, followed later by resolution of eosinophilia. Of 25 patients with eosinophilia, 15 patients (60%) had resolution of eosinophilia (AEC<500/ul) by day 32, and 7 patients (28%) resolved between day 32 – day 53, 2 patients (8%) resolved between day 54-day 95 and only one patient had persistent eosinophilia for more than 6 months before resolution after worm removal. Of all 28 patients who had serial blood counts for 6-9 months after initial treatment, it was observed that the AEC became <200/ul in 23 patients, and below 100/ul in 18 patients. Around half of the patients had normal eosinophil count (AEC<200/ul) by 3 months (day 83), and AEC<100/ul by 6 months (day 193) after parasite removal. Most (75%) had normal AEC (<200/ul) around 6 months (between day 180 and 194, Fig. 1) after parasite removal. Among all 3 patients who had normal range of AEC before initial treatment, after the worms were removed, the AEC reached a minimal level (range from 46.5-87/ul), which was approximately an 80% decrease within 3 months.

Discussion

Eosinophilia is commonly associated with gnathostomiasis(12,13). The authors found that the positive rate of eosinophilia in a proven case of cutaneous gnathostomiasis was 89%. Treatment with albendazole may immediately kill the parasite and is likely to induce the migration toward the upper epidermis. At present, there are 3 parameters for practical use to evaluate the

Table 1. The skin involvement site and the severity of eosinophilia at the time of diagnosis

<table>
<thead>
<tr>
<th>Site of skin involvement</th>
<th>Total Patients</th>
<th>Blood eosinophilia: No. (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Patients</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Head and neck</td>
<td>5 (17.8%)</td>
<td>Normal: 3 (255-380/ul)</td>
</tr>
<tr>
<td>Upper extremities</td>
<td>15 (53.4%)</td>
<td>Mild eosinophilia: 21 (525-1430/ul)</td>
</tr>
<tr>
<td>Trunk</td>
<td>2 (7.1%)</td>
<td>Moderate eosinophilia: 3 (1910-2424/ul)</td>
</tr>
<tr>
<td>Lower extremities</td>
<td>6 (21.2%)</td>
<td>Severe eosinophilia: 1 (12,800/ul)</td>
</tr>
</tbody>
</table>

Fig. 1 Resolution of eosinophilia after albendazole and worm removal
response to treatment. Firstly, the disappearance of cutaneous swelling, it may occur as the worm migrates deeper into the human tissue; or when the worm is killed and destroyed. Thus, absence of skin lesions does not essentially imply that the worm has been eradicated or the patient cured. Secondly, Gnathostoma-specific antibody titer measured by ELISA (14,15), the decreasing of titer can predict the result of treatment but this parameter is not appropriate for short-term follow-up as test results take over 6 months (10,11,16). Finally, disappearance of eosinophilia, from the present study, the decreasing AEC <500/ul could be obtained in a timelier manner and is a highly appropriate indicator for responsiveness to treatment in cutaneous gnathostomiasis. After the worm removal, 24 from 25 patients (96%) had resolution of eosinophilia within 3 months. The eosinophilia persisted for more than 3 months in only one patient; possibly due to the residuals of the worm inside the body that still induced the production of eosinophil. The resolution of eosinophil levels after treatment was gradual, ranging from several weeks to months after initial treatment. The AEC>500/ul has been customarily defined as eosinophilia, and is useful for clinical diagnosis. The true baseline AEC in uninfected patient is very low. Because AEC<200/ul, but not <100/ul, is achieved in most subjects in this study, we used AEC <200/ul as a cut-off level for ‘normal’ eosinophil count. In case of patients with normal AEC, after treatment, the level of AEC should decrease to lower than 80% from the baseline of each patient. Our study suggests that the dynamics of AEC in the proven case of cutaneous gnathostomiasis before and after treatment should be useful as follow-up guidelines in patients that parasites were never recovered. The AEC would be a practical parameter diagnosis and follow-up patients with gnathostomiasis, especially in remote areas where Western blot analysis or ELISA to detect specific antibodies are not widely available. In conclusion, eosinophilia is an important hallmark of cutaneous gnathostomiasis and its resolution could be the earlier indicator for responsiveness to treatment.

Acknowledgments

The authors wish to thank Associate Professor Phisai Kraivichian, Mr. Paisai Yingyourd, Miss Savitree Chandraprasert and Mr. Poopapat Lohachitanont for their kind advice and revising the manuscript.

References
